Genetics of Idiopathic Hypogonadotropic Hypogonadism

Over 60 genes are now linked to a puberty-blocking disorder, but genetics still explains only half of cases

Journal: Journal of Clinical Research in Pediatric Endocrinology | Published: 2025-09-17 | Type: Review | PMID: 40958510 Authors: Topaloğlu A. Kemal (Harvard Medical School, Massachusetts General Hospital); Kotan Leman Damla (Çukurova University Faculty of Medicine, Türkiye) Funding/COI: No funding listed. One author sits on the journal's editorial board but was walled off from the manuscript's review; no other conflicts declared.

Summary

This is a narrative review of the genetics behind idiopathic hypogonadotropic hypogonadism (IHH), a disorder where the brain fails to properly signal the gonads, stalling puberty and causing infertility. The authors summarize two decades of sequencing work that has turned IHH from a genetic black box into a condition with over 60 implicated genes — while also laying out why genetic testing still can't explain roughly half of all cases.

Claims

• Pathogenic variants have been identified in more than 60 genes, together accounting for up to 50% of IHH cases — meaning the other half remains genetically unexplained.
• Oligogenic inheritance (variants in more than one gene contributing to disease) occurs in an estimated 10-20% of patients, complicating simple single-gene models.
• A subset of patients experience spontaneous or treatment-induced reversal of their hypogonadism, and IHH's phenotype can overlap with constitutional delay of growth and puberty — both described as sources of diagnostic confusion.
• Research into IHH genetics identified kisspeptin, neurokinin B, and dynorphin (KNDy) neurons as the brain's GnRH "pulse generator."
• That KNDy pathway discovery fed directly into drug development: fezolinetant, a neurokinin B receptor antagonist, was FDA-approved for menopausal vasomotor symptoms (hot flashes) — a treatment born out of pediatric hypogonadism research, not menopause research.

Study Quality

This is a narrative review, not a systematic review or meta-analysis — the authors don't describe a search strategy, inclusion criteria, or a formal method for selecting the literature they cite. That's a legitimate format for synthesizing a fast-moving genetics field, but it means the "60+ genes" and "50% of cases" figures are stated as consensus numbers rather than derived from a reproducible quantitative synthesis, and readers can't independently gauge selection bias.

No primary data is generated here — there's no patient cohort, no new sequencing results, no sample size to evaluate. The value of the paper is in how well it organizes existing findings, and on that front the scope (Kallmann syndrome vs. normosmic IHH, oligogenicity, phenotypic reversal, KNDy neurobiology) is comprehensive for a field this fragmented.

Red Flags

• No stated search methodology or PRISMA-style reporting for a review making field-wide quantitative claims (60+ genes, 50% of cases, 10-20% oligogenic).
• No funding source disclosed at all — unclear if this was unfunded or simply undocumented.
• One author's editorial board membership at the publishing journal, even with a walled-off review process, is worth noting for readers.

Strengths

• Written by researchers with a substantial publication record in GnRH neurobiology and IHH genetics specifically.
• Directly connects basic genetic discovery (KNDy neurons) to an approved drug (fezolinetant), giving readers a concrete translational payoff rather than abstract gene-counting.
• Explicitly flags diagnostic pitfalls (phenotypic reversal, overlap with constitutional delay of puberty) rather than presenting IHH genetics as a solved problem.

Verdict

A useful, well-organized synthesis of a genetically messy disorder, but read it as an expert's map of the field, not as evidence in itself — there's no methodology section to interrogate, and the headline numbers should be treated as informed estimates rather than data. The most interesting single fact here isn't about IHH at all: a menopause drug on pharmacy shelves today exists because someone was trying to understand why some kids never go through puberty.